JC Virus Detection via Capsid Amino Acid Mutations
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods fail to effectively determine susceptibility to progressive multifocal leukoencephalopathy (PML) in individuals, particularly those with compromised immune systems, due to the lack of specific markers for JC polyomavirus variants that contribute to the disease progression.
Innovation Solution
Identification of specific amino acid mutations in the JC virus capsid protein, such as substitutions at positions 122, 2, 66, and deletions at 50-51, 123-125, which are associated with increased risk of PML, allowing for the development of methods to assess a subject's risk profile and monitor for early signs of the disease.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current detection methods are used, then general JCV infection can be detected, but specific PML-risk variants cannot be identified
Solution Approach 1:
The invention segments the JCV detection process by identifying specific amino acid positions (122, 2, 66) and deletion regions (50-51, 123-125) in the capsid protein that distinguish PML-risk variants from general JCV infections. This segmentation allows targeted detection of pathogenic variants while maintaining method simplicity through focused analysis of critical regions.
Solution Approach 2:
The invention applies local quality by concentrating detection efforts on specific critical amino acid positions and deletion regions within the JCV capsid protein structure. Rather than analyzing the entire virus genome, the method focuses on localized regions (positions 122, 2, 66 and deletions at 50-51, 123-125) that have been shown to correlate with PML risk, thereby improving detection specificity without proportionally increasing complexity.
2Productivity
If immunosuppressive treatment is administered, then underlying conditions are treated, but PML risk increases in JCV-infected subjects
Solution Approach 1:
The invention enables preliminary action by detecting PML-risk JCV variants before initiating immunosuppressive therapy. By screening for specific amino acid mutations and deletions in the JCV capsid protein prior to treatment, clinicians can identify high-risk subjects and take preventive measures, such as selecting alternative therapies or implementing monitoring protocols, thereby mitigating PML risk while still addressing the underlying condition requiring immunosuppression.
Solution Approach 2:
The invention implements feedback by establishing a detection system that provides information about JCV variant status to guide treatment decisions. The identification of specific molecular markers (amino acid substitutions at positions 122, 2, 66 and deletions at 50-51, 123-125) creates a feedback loop where detection results directly inform whether immunosuppressive therapy should be administered, modified, or avoided, thereby balancing treatment effectiveness with PML risk management.
Data Source
Figure 1
Figure 2
Figure 3-1
AI summary
Methods and compositions for determining whether a subject is at risk for PML, including subjects being treated with immunosuppressants by determining whether the subject harbors a ICV variant with reduced binding for sialic acid relative to a normal ICV, are presented. Furthermore, combinations of JCV-VP1 sequence variations that are associated with PML and that can be used as a basis of an assay for identifying subjects susceptible to PML, subjects with PML (e.g., early stage PML), or subjects at risk of developing PML in response to an immunosuppressive treatment are provided